DOCSLIB.ORG

Winter 2019 Lbicnews from the London Bioscience Innovation Centre

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Winter 2019 Lbicnews from the London Bioscience Innovation Centre Winter 2019 LBICnews From the London BioScience Innovation Centre WELCOME It is good to be back after my maternity leave and see all the exciting updates from our clients. It is wonderful to hear of funding successes and international collaborations, showing that bioscience is still a key sector in the UK economy. Such successes need publicising. On page 7, Sciad gives us advice on creating the perfect press release. There have been some departures during my leave as companies outgrow their LBIC space, but this Prokarium secures £4.6m allows us to welcome new clients in their place, most recently leading ophthalmology company Gyroscope, from Wellcome to fund profiled on page 6. In this issue, we also feature the vaccine against enteric fever LBIC team, to give a little insight into who we all are. Turn to pages 4 and 5 Ted Fjallman, Prokarium CEO (left) and Daniel Gill, Business Development Associate, Wellcome Trust if you would like to find out who bakes, who enjoys sea kayaking and Prokarium has received an investment of £4.59 million from the Wellcome who cooks fufu. Trust to fund two clinical trials of its lead programme, Entervax™, a vaccine against enteric fever. Enteric fever, primarily caused by bivalent vaccine that has the potential to Lucy Garnsworthy, Editor Salmonella enterica serovars Typhi and decrease the use of antimicrobials in the Paratyphi A, is the most common bacterial fight against antimicrobial resistance and to bloodstream infection in South Asia and provide a significant public health benefit to In this issue: causes significant mortality in areas with individuals at risk. poor sanitation. “Funding from a prestigious foundation Prokarium funding Lead story “This is the first new investment such as the Wellcome Trust underlines the deltaDOT launch in China Page 3 Wellcome has made within its new strength of our approach and provides the Meet the LBIC team Pages 4-5 Affordable Innovations for Global Health support necessary to progress to the clinic,” Gyroscope Therapeutics Flagship”, said Sally Nicholas, Partner, the said Ted Fjallman, Ph.D, Chief Executive expands to LBIC Page 6 Wellcome Trust. The collaboration shows Officer, Prokarium. Rules for the perfect press release Page 7 the joint commitment to develop a novel Client News Round-up Funding to help Virokine Therapeutics Ori manufacture reports preclinical brighter futures studies with NIH Ori Biotech are very pleased to announce Virokine Therapeutics Ltd (VTL), a new the finalisation of their seed funding round, start-up at01 LBIC, is excited to report the 02 after making their home at LBIC earlier this launch of its preclinical studies of VTL year. Ori’s disruptive manufacturing immunotherapeutics with an award from the technology for cell and gene therapies National Institutes of Health (NIH) in the promises a new way to produce these living USA. This is in medicines and Ori is now fully primed to collaboration take on the challenge of the commercial- with leading level scale that the industry needs. Their Fabrican’s drink seal experts in DNA vaccination at the long-term aim is to enable access for all Cincinnati Children’s Hospital and the patients to the hope and promise that cell Fabrican’s spray-on University of Louisiana Veterinary School. and gene therapy brings. sterile seal for canned VTL is 03engaging in further in vitro studies 04 to complement this work and associated IP drinks with support from a recent round of USA Business Angel Seed investment. New Fabrican has produced a sterile, appointments for this work include biodegradable spray-on coating to seal the Research Assistant Laboratory Manager, top of a drinks can. The innovative formula Sean Briggs, with first class and distinction will be sprayed during the packaging BSc/MSc degrees in immunology from process, protecting the can from dust and Newcastle University. The Scientific bacteria so consumers can peel then drink Advisory Board members are joined by Dr from a sterile surface. Persephone Borrow, Professor of Viral The Ori Biotech team Fabrican aims to minimise packaging Immunology at the University of Oxford, Dr waste and improve the convenience of Jane Minton, Clinical Consultant and transporting six-pack cans. The coating Associate Professor in Infectious Diseases, removes the need for traditional rings that “We feel at home at LBIC Trials Leader at NIHR and NHS Hospital can harm the environment and it degrades and hope to use our new University of Leeds, and Dr Ann Kwong, in compost or seawater. It can be Pharma Consulting LLC, Boston, USA. VTL funding to expand customised with colour for specific brands also welcomes Corporate Finance Director, operations as we bring our and can even be infused with scent. Michael Martin, experienced investment proprietary cell and gene The formulation is composed of natural banker and biotechnology start-up advisor. fibres, a biodegradable polymeric resin and therapy manufacturing VTL has recently joined key other additives. The texture of the formula platform to market” biotechnology industry networks as an has the feel of a non-woven material and is affiliate of the new Milner Institute at the not limited by can size. This unique University of Cambridge and as a member application has created much interest in the CEO of Ori Biotech, Jason Foster of One Nucleus. beverage industry to address the growing environmental concerns of consumers. www.fabrican.co.uk LBIC welcomes these new clients to the Centre: • Evelobio • Freeline Therapeutics • Drive Phase PV • Gyroscope Therapeutics • Scalene • Sporegen Dr Ursula Gompels, Virokine CEO/CSO, speaking at the Anglonordic Life Science Conference 2 London BioScience Innovation Centre News Winter 2019 deltaDOT launch in China deltaDOT’s Capillary Electrophoresis molecules and is particularly useful product (known as the HPCE-512) has when characterising a complex been launched in China by Hanon mixture or quantitating specific Instruments. This product has been analytes (e.g. mAb and vaccine manufactured by Hanon with assistance stability studies). from deltaDOT over the past two years. The Nigel Stokes, Managing Director version manufactured in China is the same of deltaDOT, commented: “It is a instrument, but with a new colour scheme great achievement by both our and that reflects the colours in Hanon’s logo. Hanon’s technical teams that this Hanon plan to sell the HPCE-512 to clients product is now being manufactured in the academic, pharmaceutical, and sold in China. We believe that biotechnology and manufacturing sectors in the product will prove very useful for China and the Pacific Rim countries. The many QA/QC applications.” Launch of deltaDOT’s HPCE-512 at a recent HPCE-512 analyses a wide range of trade show in Beijing Introducing Drive Phase PV LBIC welcomes new client • Eudravigilance services personalised PV support to clients around Drive Phase PV, experts • Risk Management Plans and signal the world. in pharmacovigilance. detection Tom is an Honorary Fellow of the • UK Qualified Person for Pharmaceutical Information and Drive Phase PV provides pharmacovigilance Pharmacovigilance and deputy Pharmacovigilance Association (HonFPIPA) (PV), device-vigilance and auditing services services and has served on the committee for in both clinical and post-marketing settings, • Periodic report preparation several years, collaborating on documents with particular expertise in oncology • Pharmacovigilance System Masterfile such as guidelines for clinical and post- and biologics. creation and maintenance marketing PV and implementing GDPR • Standard Operating Procedure requirements for PV departments. Services include: creation and maintenance He is also a member of the Alliance for • PV system design and optimisation Director Tom Nichols has worked across Clinical Research Excellence and Safety • Audit and Corrective and Preventative the full PV spectrum from early-phase (ACRES) working group, developing Action management clinical trials through to generics. Following standards for the outsourcing of PV • Safety database updates a period heading up the PV function at a activities, and co-leads the Drug Information and migration leading clinical research organisation Association (DIA) pre-market safety • Safety Data Exchange Agreement (CRO), Drive Phase PV was launched with working group. preparation and management the goal of providing high-quality and Inspiring Growth and Creating Opportunities in Life Sciences SPONSORSHOWCASEATTEND LONDONAPRIL28-292020 Meet the LBIC Ken Larkin Janette Pickles CEO Operations Manager YEAR JOINED: 2009 YEAR JOINED: 2007 Ken lives in the East Midlands with his wife, Team Janette lives in Aylesbury with the love of their daughter and two dogs. In his spare her life, her seven-year-old Border Collie, time, he enjoys going out on one of his Indy. She enjoys nothing more than taking many bikes and clocking up the miles on him for long walks come rain or shine. She Strava. Ken is pleased to have a few bakers also enjoys good food and a glass of wine within the LBIC team, and is always happy whilst watching a bit of rugby. to sample the treats that they bring in. Lucy Garnsworthy Roo Goodwin Mariane Meyer Communications Manager Administration Manager Administrator YEAR JOINED: 2010 YEAR JOINED: 2018 YEAR JOINED: 2005 Lucy lives in London with a French man and Roo lives in Bedfordshire with her husband, Outside of the office, Mariane loves to read their baby girl, born in 2018. Lucy used to two miniature schnauzers Sprocket and and listen to music. When she can, she work as an archaeologist excavating Doozer, cat Hershel and rabbit Nutkin. She heads home to South Africa to see her building sites all over southeast England, enjoys running (slowly) with her local club, children and grandchildren. She recently and excavated on Dartmoor and in listening to podcasts, frequently going to met the new man in her life, little grandson Honduras during her studies at UCL. She see her favourite band play live and baking Benjamin, who has just turned one.
Load more

Recommended publications
  • Transcriptomic Profiles of High and Low Antibody Responders to Smallpox
    Genes and Immunity (2013) 14, 277–285 & 2013 Macmillan Publishers Limited All rights reserved 1466-4879/13 www.nature.com/gene ORIGINAL ARTICLE Transcriptomic profiles of high and low antibody responders to smallpox vaccine RB Kennedy1,2, AL Oberg1,3, IG Ovsyannikova1,2, IH Haralambieva1,2, D Grill1,3 and GA Poland1,2 Despite its eradication over 30 years ago, smallpox (as well as other orthopox viruses) remains a pathogen of interest both in terms of biodefense and for its use as a vector for vaccines and immunotherapies. Here we describe the application of mRNA-Seq transcriptome profiling to understanding immune responses in smallpox vaccine recipients. Contrary to other studies examining gene expression in virally infected cell lines, we utilized a mixed population of peripheral blood mononuclear cells in order to capture the essential intercellular interactions that occur in vivo, and would otherwise be lost, using single cell lines or isolated primary cell subsets. In this mixed cell population we were able to detect expression of all annotated vaccinia genes. On the host side, a number of genes encoding cytokines, chemokines, complement factors and intracellular signaling molecules were downregulated upon viral infection, whereas genes encoding histone proteins and the interferon response were upregulated. We also identified a small number of genes that exhibited significantly different expression profiles in subjects with robust humoral immunity compared with those with weaker humoral responses. Our results provide evidence that differential gene regulation patterns may be at work in individuals with robust humoral immunity compared with those with weaker humoral immune responses. Genes and Immunity (2013) 14, 277–285; doi:10.1038/gene.2013.14; published online 18 April 2013 Keywords: Next-generation sequencing; mRNA-Seq; vaccinia virus; smallpox vaccine INTRODUCTION these 44 subjects had two samples (uninfected and vaccinia Vaccinia virus (VACV) is the immunologically cross-protective infected).
    [Show full text]
  • Investigation of the C-Terminal Helix of HIV-1 Matrix: a Region Essential for Multiple Functions in the Viral Life Cycle: a Dissertation
    University of Massachusetts Medical School eScholarship@UMMS GSBS Dissertations and Theses Graduate School of Biomedical Sciences 2011-07-10 Investigation of the C-Terminal Helix of HIV-1 Matrix: A Region Essential for Multiple Functions in the Viral Life Cycle: A Dissertation Laura A. Brandano University of Massachusetts Medical School Let us know how access to this document benefits ou.y Follow this and additional works at: https://escholarship.umassmed.edu/gsbs_diss Part of the Biological Factors Commons, Genetic Phenomena Commons, Immunology and Infectious Disease Commons, Therapeutics Commons, Virology Commons, Virus Diseases Commons, and the Viruses Commons Repository Citation Brandano LA. (2011). Investigation of the C-Terminal Helix of HIV-1 Matrix: A Region Essential for Multiple Functions in the Viral Life Cycle: A Dissertation. GSBS Dissertations and Theses. https://doi.org/ 10.13028/5zmj-9x81. Retrieved from https://escholarship.umassmed.edu/gsbs_diss/552 This material is brought to you by eScholarship@UMMS. It has been accepted for inclusion in GSBS Dissertations and Theses by an authorized administrator of eScholarship@UMMS. For more information, please contact [email protected]. i INVESTIGATION OF THE C-TERMINAL HELIX OF HIV-1 MATRIX: A REGION ESSENTIAL FOR MULTIPLE FUNCTIONS IN THE VIRAL LIFE CYCLE A Dissertation Presented by Laura A. Brandano Submitted to the Faculty of the University of Massachusetts Graduate School of Biomedical Sciences, Worcester in partial fulfillment of the requirements for the degree of DOCTOR
    [Show full text]
  • “Molecular Fingerprints” Using an EBV (Epstein-Barr Virus)-D
    Immunologic Research (2018) 66:686–695 https://doi.org/10.1007/s12026-018-9045-0 REVIEW Molecular mimicry, genetic homology, and gene sharing proteomic Bmolecular fingerprints^ using an EBV (Epstein-Barr virus)-derived microarray as a potential diagnostic method in autoimmune disease David H. Dreyfus1 & Antonella Farina2 & Giuseppina Alessandra Farina3 David H. Dreyfus Published online: 15 December 2018 # The Author(s) 2018 Abstract EBV (Epstein-Barr Virus) and other human DNA viruses are associated with autoimmune syndromes in epidemiologic studies. In this work, immunoglobulin G response to EBV-encoded proteins which share regions with human immune response proteins from the human host including ZEBRA (BZLF-1 encoded protein), BALF-2 recombinase expressed primarily during the viral lytic replication cycle, and EBNA-1 (Epstein-Barr Virus Nuclear Antigen) expressed during the viral latency cycle respectively were characterized using a laser-printed micro-array (PEPperprint.com). IgG response to conserved BA/T hooks^ in EBV- encoded proteins such as EBNA-1 and the BALF-2 recombinase related to host DNA-binding proteins including RAG-1 recombinase and histones, and EBV-encoded virokines such as the IL-10 homologue BCRF-1 suggest further directions for clinical research. The author suggests that proteomic Bmolecular fingerprints^ of the immune response to viral proteins shared with human immune response genes are potentially useful in early diagnosis and monitoring of autoantibody production and response to therapy in EBV-related autoimmune syndromes. Keywords Molecular mimicry . Autoimmune disease . SLE (systemic lupus erythematosus) . Scleroderma . MS (multiple sclerosis) . Virokine Introduction available using specific immunoglobulin G (IgG) binding to viral proteins such as EBNA-1 (Epstein-Barr Virus Nuclear DNA viruses such as EBV (Epstein-Barr Virus) have been Antigen-1), VCA (Viral Capsid Antigen), and EA (viral com- associated with numerous autoimmune syndromes in epide- ponents termed Early Antigen).
    [Show full text]
  • Recovery of the First Full-Length Genome Sequence of a Parapoxvirus Directly from a Clinical Sample
    www.nature.com/scientificreports OPEN Recovery of the first full-length genome sequence of a parapoxvirus directly from a clinical sample Received: 10 January 2017 Thomas Günther1, Ludwig Haas2, Malik Alawi1,3, Peter Wohlsein4, Jerzy Marks5, Adam Accepted: 9 May 2017 Grundhoff1,6, Paul Becher 2,7 & Nicole Fischer6,8 Published: xx xx xxxx We recovered the first full-length poxvirus genome, including the terminal hairpin region, directly from complex clinical material using a combination of second generation short read and third generation nanopore sequencing technologies. The complete viral genome sequence was directly recovered from a skin lesion of a grey seal thereby preventing sequence changes due to in vitro passaging of the virus. Subsequent analysis of the proteins encoded by this virus identified genes specific for skin adaptation and pathogenesis of parapoxviruses. These data warrant the classification of seal parapoxvirus, tentatively designated SePPV, as a new species within the genus Parapoxvirus. Parapoxviruses (PPVs) form a genus of the family Poxviridae. Poxviruses are large double stranded DNA viruses with genomes of approximately 135 to 360 kbp, which contain up to 328 open reading frames1. According to the International Committee on Taxonomy of Viruses (ICTV; http://ictvonline.org/virusTaxonomy.asp), the genus Parapoxvirus comprises the following species members: the Orf virus (ORFV), considered the prototype para- poxvirus causing contagious pustular dermatitis in small ruminants, the Bovine papular stomatitis virus (BPSV), the Pseudocowpox virus (PCPV) and the Parapoxvirus of red deer in New Zealand (PVNZ). Beside these viruses with known full-length nucleotide sequences, a number of tentative species have been proposed based on the amplification of smaller genome fragments using pan-PCR primers encompassing 250–550 bp of the DNA pol- ymerase, DNA topoisomerase I and major envelope protein encoding regions.
    [Show full text]
  • Viral Infections and Systemic Lupus Erythematosus: New Players in an Old Story
    viruses Review Viral Infections and Systemic Lupus Erythematosus: New Players in an Old Story Marco Quaglia 1,2, Guido Merlotti 1,2 , Marco De Andrea 2,3 , Cinzia Borgogna 2,4 and Vincenzo Cantaluppi 1,2,* 1 Nephrology and Kidney Transplantation Unit, Department of Translational Medicine, University of Piemonte Orientale (UPO), “Maggiore della Carità” University Hospital, Via P. Solaroli 17, 28100 Novara, Italy; [email protected] (M.Q.); [email protected] (G.M.) 2 Center for Translational Research on Autoimmune and Allergic Disease-CAAD, 28100 Novara, Italy; [email protected] (M.D.A.); [email protected] (C.B.) 3 Department of Public Health and Pediatric Sciences, Medical School, University of Turin, 10126 Turin, Italy 4 Department of Translational Medicine, University of Piemonte Orientale (UPO), 28100 Novara, Italy * Correspondence: [email protected] Abstract: A causal link between viral infections and autoimmunity has been studied for a long time and the role of some viruses in the induction or exacerbation of systemic lupus erythematosus (SLE) in genetically predisposed patients has been proved. The strength of the association between different viral agents and SLE is variable. Epstein–Barr virus (EBV), parvovirus B19 (B19V), and human endogenous retroviruses (HERVs) are involved in SLE pathogenesis, whereas other viruses such as Cytomegalovirus (CMV) probably play a less prominent role. However, the mechanisms of viral–host interactions and the impact of viruses on disease course have yet to be elucidated. In addition to classical mechanisms of viral-triggered autoimmunity, such as molecular mimicry and Citation: Quaglia, M.; Merlotti, G.; epitope spreading, there has been a growing appreciation of the role of direct activation of innate De Andrea, M.; Borgogna, C.; response by viral nucleic acids and epigenetic modulation of interferon-related immune response.
    [Show full text]
  • Evolution Toward Beta Common Chain Receptor Usage Links the Matrix Proteins of HIV-1 and Its Ancestors to Human Erythropoietin
    Evolution toward beta common chain receptor usage links the matrix proteins of HIV-1 and its ancestors to human erythropoietin Francesca Caccuria,1, Pasqualina D’Ursib,1, Matteo Uggerib,c, Antonella Bugattia, Pietro Mazzucaa, Alberto Zania, Federica Filippinia, Mario Salmonad, Domenico Ribattie, Mark Slevinf, Alessandro Orrob, Wuyuan Lug, Pietro Liòh, Robert C. Gallog,2, and Arnaldo Carusoa,2 aDepartment of Molecular and Translational Medicine, University of Brescia Medical School, 25123 Brescia, Italy; bInstitute of Technologies in Biomedicine, National Research Council, 20090 Segrate, Italy; cDepartment of Pharmacy, University of Genova, 16132 Genova, Italy; dIstituti di Ricovero e Cura a Carattere Assistenziale Istituto di Ricerche Farmacologiche Mario Negri, 20156 Milan, Italy; eDepartment of Basic Medical Sciences, Neurosciences and Sensory Organs, University of Bari Medical School, 70124 Bari, Italy; fSchool of Healthcare Science, Manchester Metropolitan University, M15GD Manchester, United Kingdom; gInstitute of Human Virology, University of Maryland, Baltimore, MD 21201; and hDepartment of Computer Science and Technology, University of Cambridge, CB3 0FD Cambridge, United Kingdom Contributed by Robert C. Gallo, December 1, 2020 (sent for review October 14, 2020; reviewed by Leonid B. Margolis and Guido Silvestri) The HIV-1 matrix protein p17 (p17) is a pleiotropic molecule impacting envelope glycoproteins (6). Interestingly, HIV-1–infected cells can on different cell types. Its interaction with many cellular proteins un- unconventionally secrete p17 following Pr55Gag binding to phos- derlines the importance of the viral protein as a major determinant of phatidylinositol 4, 5-bisphosphate and p17 cleavage from Pr55Gag human specific adaptation. We previously showed the proangiogenic (7). Secretion of p17 occurs also in the absence of viral protease capability of p17.
    [Show full text]
  • Understanding Poxvirus Pathogenesis by Selectively Deleting Viral Immunomodulatory Genes Johnston, J
    NRC Publications Archive Archives des publications du CNRC Technical knockout: understanding poxvirus pathogenesis by selectively deleting viral immunomodulatory genes Johnston, J. B.; McFadden, Grant This publication could be one of several versions: author’s original, accepted manuscript or the publisher’s version. / La version de cette publication peut être l’une des suivantes : la version prépublication de l’auteur, la version acceptée du manuscrit ou la version de l’éditeur. For the publisher’s version, please access the DOI link below./ Pour consulter la version de l’éditeur, utilisez le lien DOI ci-dessous. Publisher’s version / Version de l'éditeur: https://doi.org/10.1111/j.1462-5822.2004.00423.x Cellular Microbiology, 6, June 8, pp. 695-705, 2004 NRC Publications Record / Notice d'Archives des publications de CNRC: https://nrc-publications.canada.ca/eng/view/object/?id=a646f73c-5476-4961-9fd4-9ebff270b279 https://publications-cnrc.canada.ca/fra/voir/objet/?id=a646f73c-5476-4961-9fd4-9ebff270b279 Access and use of this website and the material on it are subject to the Terms and Conditions set forth at https://nrc-publications.canada.ca/eng/copyright READ THESE TERMS AND CONDITIONS CAREFULLY BEFORE USING THIS WEBSITE. L’accès à ce site Web et l’utilisation de son contenu sont assujettis aux conditions présentées dans le site https://publications-cnrc.canada.ca/fra/droits LISEZ CES CONDITIONS ATTENTIVEMENT AVANT D’UTILISER CE SITE WEB. Questions? Contact the NRC Publications Archive team at [email protected]. If you wish to email the authors directly, please see the first page of the publication for their contact information.
    [Show full text]
  • Characterization of Swinepox Virus Secretory Polypeptides
    Western Michigan University ScholarWorks at WMU Master's Theses Graduate College 4-1998 Characterization of Swinepox Virus Secretory Polypeptides Takeshi Shimamura Follow this and additional works at: https://scholarworks.wmich.edu/masters_theses Part of the Biology Commons Recommended Citation Shimamura, Takeshi, "Characterization of Swinepox Virus Secretory Polypeptides" (1998). Master's Theses. 4576. https://scholarworks.wmich.edu/masters_theses/4576 This Masters Thesis-Open Access is brought to you for free and open access by the Graduate College at ScholarWorks at WMU. It has been accepted for inclusion in Master's Theses by an authorized administrator of ScholarWorks at WMU. For more information, please contact [email protected]. CHARACTERIZATION OF SWINEPOX VIRUS SECRETORY POLYPEPTIDES by Takeshi Shimamura A Thesis Submitted to the Faculty of The Graduate College in partial fulfillment of the requirements for the Degree of Master of Science Department of Biological Sciences Western Michigan University Kalamazoo, Michigan April 1998 Copyright by Takeshi Shimamura 1998 ACKNOWLEDGEMENTS I wish to express my high regard and appreciation to my advisor and mentor, Dr. Karim Essani for his guidance and help throughout this study. I am thankful to Dr. Robert C. Eisenberg, and Dr. Ronald C. Shebuski for taking the time to be a part of my thesis committee. Cardiovascular studies were carried out in Dr. Ronald Shebuski's laboratory. I also thank Dr. Anthony Manning forhis generosity to allow me to work in his laboratory on the cell adhesion molecules. Thanks also to Mr. William R. Humphrey for his help in the cardiovascular study, Ms. Jennifer L. Northrup, Ms. Cynthia J. Mills, and Ms.
    [Show full text]
  • Neuropathologic Implication of Peripheral Neuregulin-1 and EGF
    Hindawi Publishing Corporation BioMed Research International Volume 2014, Article ID 697935, 12 pages http://dx.doi.org/10.1155/2014/697935 Review Article Neuropathologic Implication of Peripheral Neuregulin-1 and EGF Signals in Dopaminergic Dysfunction and Behavioral Deficits Relevant to Schizophrenia: Their Target Cells and Time Window Hiroyuki Nawa, Hidekazu Sotoyama, Yuriko Iwakura, Nobuyuki Takei, and Hisaaki Namba Department of Molecular Neurobiology, Brain Research Institute, Niigata University, 1-757 Asahimachi-dori, Chuo-ku, Niigata 951-8585, Japan Correspondence should be addressed to Hiroyuki Nawa; [email protected] Received 1 February 2014; Accepted 10 April 2014; Published 13 May 2014 Academic Editor: Saverio Bellusci Copyright © 2014 Hiroyuki Nawa et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Neuregulin-1 and epidermal growth factor (EGF) are implicated in the pathogenesis of schizophrenia. To test the developmental hypothesis for schizophrenia, we administered these factors to rodent pups, juveniles, and adults and characterized neurobiological and behavioral consequences. These factors were also provided from their transgenes or infused into the adult brain. Herewe summarize previous results from these experiments and discuss those from neuropathological aspects. In the neonatal stage but not the juvenile and adult stages, subcutaneously injected factors penetrated the blood-brain barrier and acted on brain neurons, which later resulted in persistent behavioral and dopaminergic impairments associated with schizophrenia. Neonatally EGF-treated animals exhibited persistent hyperdopaminergic abnormalities in the nigro-pallido-striatal system while neuregulin-1 treatment resulted in dopaminergic deficits in the corticolimbic dopamine system.
    [Show full text]
  • Structure-Function Studies of the Vaccinia Virus Complement Control Protein
    University of Louisville ThinkIR: The University of Louisville's Institutional Repository Electronic Theses and Dissertations 8-2002 Structure-function studies of the vaccinia virus complement control protein. Scott Alan Smith University of Louisville Follow this and additional works at: https://ir.library.louisville.edu/etd Recommended Citation Smith, Scott Alan, "Structure-function studies of the vaccinia virus complement control protein." (2002). Electronic Theses and Dissertations. Paper 1347. https://doi.org/10.18297/etd/1347 This Doctoral Dissertation is brought to you for free and open access by ThinkIR: The University of Louisville's Institutional Repository. It has been accepted for inclusion in Electronic Theses and Dissertations by an authorized administrator of ThinkIR: The University of Louisville's Institutional Repository. This title appears here courtesy of the author, who has retained all other copyrights. For more information, please contact [email protected]. STRUCTURE-FUNCTION STUDIES OF THE VACCINIA VIRUS COMPLEMENT CONTROL PROTEIN By Scott Alan Smith A.S. Community College of Allegheny County, 1995 B.S. California University of Pennsylvania, 1997 A Dissertation Submitted to the Faculty of the Graduate School of the University of Louisville in Partial Fulfillment of the Requirements for the Degree of Doctor of Philosophy Department of Microbiology and Immunology University of Louisville Louisville, Kentucky August 2002 STUCTURE-FUNCTION STUDIES OF THE VACCINIA VIRUS COMPLEMENT CONTROL PROTEIN By Scott Alan Smith
    [Show full text]
  • Cytokine Diedel and a Viral Homologue Suppress the IMD Pathway in Drosophila
    Cytokine Diedel and a viral homologue suppress the IMD pathway in Drosophila Olivier Lamiablea, Christine Kellenbergerb, Cordula Kempa, Laurent Troxlera, Nadège Peltec, Michael Boutrosc, Joao Trindade Marquesd, Laurent Daefflera, Jules A. Hoffmanna,e, Alain Rousselb, and Jean-Luc Imlera,e,f,1 aInstitut de Biologie Moleculaire et Cellulaire, CNRS-Unité Propre de Recherche 9022, 67084 Strasbourg, France; bArchitecture et Fonction des Macromolécules Biologiques, CNRS and Université Aix-Marseille, Unité Mixte de Recherche 7257, 13288 Marseille, France; cDepartment of Cell and Molecular Biology, Division of Signaling and Functional Genomics and University of Heidelberg, Medical Faculty Mannheim, German Cancer Research Center, 69120 Heidelberg, Germany; dDepartment of Biochemistry and Immunology, Instituto de Ciências Biológicas, Universidade Federal de Minas Gerais, CEP30270-901 Belo Horizonte, Brazil; eUniversity of Strasbourg Institute for Advanced Studies, Université de Strasbourg, 67084 Strasbourg, France; and fFaculté des Sciences de la Vie, Université de Strasbourg, 67083 Strasbourg, France Edited by Alexander S. Raikhel, University of California, Riverside, CA, and approved December 11, 2015 (received for review August 13, 2015) Viruses are obligatory intracellular parasites that suffer strong acts through the p105-like transcription factor Relish (3, 5). It is evolutionary pressure from the host immune system. Rapidly evocative of the tumor necrosis factor (TNF) receptor pathway evolving viral genomes can adapt to this pressure by acquiring from vertebrates. genes that counteract host defense mechanisms. For example, Previous studies have revealed that insect susceptibility to viral many vertebrate DNA viruses have hijacked cellular genes encod- infection is determined by host factors, which either facilitate (6, ing cytokines or cytokine receptors to disrupt host cell communi- 7) or restrict viral replication (8–10).
    [Show full text]
  • Molecular Genetic Analysis of Orf Virus: a Poxvirus That Has Adapted to Skin
    Viruses 2015, 7, 1505-1539; doi:10.3390/v7031505 OPEN ACCESS viruses ISSN 1999-4915 www.mdpi.com/journal/viruses Review Molecular Genetic Analysis of Orf Virus: A Poxvirus That Has Adapted to Skin Stephen B. Fleming *, Lyn M. Wise and Andrew A. Mercer Department of Microbiology and Immunology, 720 Cumberland St, University of Otago, Dunedin 9016, New Zealand; E-Mails: [email protected] (L.M.W.); [email protected] (A.A.M.) * Author to whom correspondence should be addressed; E-Mail: [email protected]; Tel.: +64-3-4797727; Fax: +64-3-4797744. Academic Editors: Elliot J. Lefkowitz and Chris Upton Received: 23 February 2015 / Accepted: 19 March 2015 / Published: 23 March 2015 Abstract: Orf virus is the type species of the Parapoxvirus genus of the family Poxviridae. It induces acute pustular skin lesions in sheep and goats and is transmissible to humans. The genome is G+C rich, 138 kbp and encodes 132 genes. It shares many essential genes with vaccinia virus that are required for survival but encodes a number of unique factors that allow it to replicate in the highly specific immune environment of skin. Phylogenetic analysis suggests that both viral interleukin-10 and vascular endothelial growth factor genes have been “captured” from their host during the evolution of the parapoxviruses. Genes such as a chemokine binding protein and a protein that binds granulocyte-macrophage colony-stimulating factor and interleukin-2 appear to have evolved from a common poxvirus ancestral gene while three parapoxvirus nuclear factor (NF)-κB signalling pathway inhibitors have no homology to other known NF-κB inhibitors.
    [Show full text]